ELA Medical, Inc, a Sorin Group company (MIL:SRN), announced today
the first U.S. implant in the Investigational Trial of the OVATIO(TM)
CRT, Cardiac Resynchronization Therapy Defibrillator, Model 6750.
The first clinical implant of OVATIO(TM) CRT-D, the smallest
biventricular ICD currently available outside the U.S. at 30cc, was
successfully performed by Dr. Eli S. Gang, Clinical Professor of
Medicine, David Geffen School of Medicine, UCLA. The implant occurred
at Brotman Medical Center, Culver City, California.
Cardiac resynchronization ICD therapy for heart failure patients
at risk of sudden cardiac death (SCD) has become a standard-of-care
treatment. Cardiac Resynchronization Therapy (CRT) has been shown,
using earlier devices, to improve quality of life, increase exercise
capacity, and reduce hospitalizations and mortality.
In patients with poor ventricular function, there is a high
incidence of slow ventricular tachycardias (VT) and these arrhythmias
have significant clinical effects. A recent publication indicated that
not maintaining CRT during exercise might not allow the patient to
experience prolonged, and eventually beneficial, physical activity.
OVATIOTM CRT's unique BTO(TM) feature (Brady-Tachy Overlap) is
designed to "Unlock Pacing and Detection" to ensure delivery of
resynchronization therapy during exercise.
"I like the fact that with the smallest CRT-D in the world I can
pace my patients during exercise as well as detect and treat slower
rate VTs without programming constraints", stated Dr. Eli Gang.
OVATIOTM CRT also includes P And R Arrhythmia Detection
(PARAD(R)/PARAD(R)+) for maximum specificity of ventricular
tachycardia. Studies using earlier ELA ICDs, demonstrated that PARAD+
has a superior specificity in discriminating atrial from ventricular
arrhythmias, without a reduction in sensitivity. For heart failure
patients, not only is it vital that life saving therapies be delivered
when necessary, but also that unnecessary and painful shocks be
avoided to improve quality of life.
"The OVATIO(TM) CRT-D reflects the Sorin Group's commitment and
dedication to the development of innovative, state-of-the-art cardiac
rhythm devices that improve patients' longevity and quality of life",
said Richard Ames, Senior Vice President, U.S. Cardiac Rhythm
Management (CRM).
About the Sorin Group
The Sorin Group (Bloomberg: SRN.IM; Reuters: SORN.MI), a world
leader in the development of medical technologies for cardiac surgery,
offers innovative therapies for cardiac rhythm dysfunctions,
interventional cardiology and the treatment of chronic kidney
diseases. The Sorin Group includes these brands: Dideco, CarboMedics,
COBE Cardiovascular, Stockert, Mitroflow, ELA Medical, Sorin
Biomedica, Bellco and Bellco-Soludia. At the Sorin Group 4,500
employees work to serve over 5,000 public and private treatment
centers in more than 80 countries throughout the world. For more
information, please visit: www.sorin.com or www.sorin-crm.com
